Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura.
about
Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical useA randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura.Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura.Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura.Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura.Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light.Treatment of thrombotic thrombocytopenic purpura.Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura.Investigational drugs in thrombotic thrombocytopenic purpura.Main Properties of the THERAFLEX MB-Plasma System for Pathogen ReductionGuidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study.Component pathogen inactivation: a critical review.Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasmaRecommendations for the transfusion of plasma and platelets.A comparison of methods of pathogen inactivation of FFP.Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period.Update on the use of pathogen-reduced human plasma and platelet concentrates.Coagulation factor content of plasma produced from whole blood stored for 24 hours at ambient temperature: results from an international multicenter BEST Collaborative study.Methylene-blue-photoinactivated plasma and its contribution to blood safety.Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen.Levels of von Willebrand factor-cleaving protease are normal in methylene blue-treated fresh-frozen plasma.Guidelines on transfusion for fetuses, neonates and older children.Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant
P2860
Q26741073-2D9FD909-2E77-4EFC-80B3-2F64C00427A1Q30441694-AE558AC4-62B3-44FC-B8ED-3B280B08FA78Q33348253-53D8A7E1-D9C8-4971-B113-201CD4563976Q33360121-251B75A0-7982-430C-B09A-5CE657150CE8Q33360800-54FFB1C4-6FF3-4620-B215-968B7D53BB83Q33368173-0305779F-C9E8-4528-A893-37CEBF0397A9Q33370956-0E6600EC-BCD9-4131-AFFC-8AABE5E0DADAQ33376161-BA9A9299-11AD-47BF-A507-64A204984163Q33395696-EFCBDD31-7EA1-43B9-AD32-6FE8277679F4Q33396311-2C65B981-728B-444C-87FB-B4FD006E7851Q33401403-81526E13-963F-4891-9FAF-0CAD03216CAFQ33424405-B4E4550B-BADE-41EA-8FFB-1EE0D39C4EB8Q34310415-BDCE80A3-4A54-49E3-98D0-362365892BCAQ37062415-AD4F6D15-E8AD-420C-8FD4-54F86E05B307Q37209117-942C9937-5ADE-448E-AD16-BB74D74B6DF6Q37776318-49C82EC0-9C64-4E71-95F8-1CE482C6B9A2Q37789774-C20BADCA-0B7C-4A56-8331-9690D4C8D64CQ38109665-B470E895-826E-454F-B62A-60A2FF1BFBF8Q43744630-07372929-E6C1-44F7-B777-D9F5F23D1D59Q44301497-DB6982BF-BC7D-48FA-98E4-291C3D509303Q46978173-1AB09BCD-8AD1-40EB-A42E-01B993F9DBF9Q50500906-867EE901-5712-4BFA-9FC9-73F52A3C11CEQ53674609-0D77D6E9-FC76-4EE2-B451-97B5A4A8991BQ56675460-20A85801-D95B-411A-9759-A71A2058FCEF
P2860
Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Role of methylene blue-treated ...... otic thrombocytopenic purpura.
@ast
Role of methylene blue-treated ...... otic thrombocytopenic purpura.
@en
Role of methylene blue-treated ...... otic thrombocytopenic purpura.
@nl
type
label
Role of methylene blue-treated ...... otic thrombocytopenic purpura.
@ast
Role of methylene blue-treated ...... otic thrombocytopenic purpura.
@en
Role of methylene blue-treated ...... otic thrombocytopenic purpura.
@nl
prefLabel
Role of methylene blue-treated ...... otic thrombocytopenic purpura.
@ast
Role of methylene blue-treated ...... otic thrombocytopenic purpura.
@en
Role of methylene blue-treated ...... otic thrombocytopenic purpura.
@nl
P2093
P2860
P1476
Role of methylene blue-treated ...... botic thrombocytopenic purpura
@en
P2093
P2860
P304
P356
10.1046/J.1365-2141.2001.02991.X
P407
P577
2001-09-01T00:00:00Z